A vs TECH
Agilent Technologies and Bio-Techne, side by side.
Prices and company dataas of yesterday's close
- ABuy moresales growth, past year8.6%
Agilent's sales grew 8.6% over the past year, and it trades at 28 times its past year's earnings, close to its usual level.
- TECHKeep15%
Analysts expect Bio-Techne's profit to grow 15% next year, but its sales grew only 0.9% over the past year.
Percent return
- A+19.31%
- TECH+23.71%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: A $39.6B, TECH $11.2B.
- Sales growth, 1 yr: A +8.6%, TECH +0.9%. A is ahead.
- Price for $1 of next year's profit: A $27, TECH $34. A is ahead.
- Profit per $1 of sales: A 25¢, TECH 21¢. A is ahead.
- Cash minus debt: A −$2.39B, TECH +$64.5M. TECH is ahead.
- Price change, 1 yr: A +19%, TECH +24%. TECH is ahead. S&P 500 +12%.
- How much the price swings: A 29%, TECH 3.1%. TECH is ahead.
| Measure | AAgilent Technologies | TECHBio-Techne |
|---|---|---|
| Price and returns | ||
| Price | $176.91 | $72.79 |
| Today | −0.55% | Best in this row: −0.04% |
| 1 month | Best in this row: +3.76% | +0.47% |
| 3 months | Best in this row: +18.52% | +1.00% |
| This year | Best in this row: +31.02% | +24.32% |
| 1 year | +19.31% | Best in this row: +23.71% |
| 5 years | Best in this row: +15.49% | −41.23% |
| From 52-week high | −2.5% | −0.1% |
| How much it swings (90 days) | 29% | Best in this row: 3% |
| Valuation | ||
| Market value | $39.6B | $11.2B |
| Price vs last year's earnings | Best in this row: 28.2× | 102.9× |
| Price vs next year's expected earnings | Best in this row: 26.6× | 34.4× |
| Price vs earnings, adjusted for growth | Best in this row: 2.20× | 5.33× |
| Price to sales | Best in this row: 6.7× | 9.3× |
| Price vs cash it brings in | 38.9× | Best in this row: 37.1× |
| Company value vs operating profit | Best in this row: 24.8× | 34.9× |
| Price vs earnings, against its own past (0 = cheapest) | 100 | – |
| Growth | ||
| Revenue growth, 1 year | Best in this row: +8.6% | +0.9% |
| Revenue growth a year, last 3 years | +0.5% | Best in this row: +2.2% |
| Earnings per share growth, last year | Best in this row: +22.8% | −15.7% |
| Earnings per share growth expected next year | +8.0% | Best in this row: +15.0% |
| Profitability | ||
| Kept from sales after making the product | 53.6% | Best in this row: 66.2% |
| Kept as operating profit | Best in this row: 24.5% | 21.4% |
| Kept as final profit | Best in this row: 19.5% | 14.0% |
| Kept as spare cash | 17.2% | Best in this row: 25.1% |
| Profit on shareholders' money | Best in this row: 21.0% | 8.3% |
| Profit on all money put in | Best in this row: 16.9% | 9.4% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$2.39B | Best in this row: $64.5M |
| Debt for each $1 of shareholders' money | 0.56× | Best in this row: 0.13× |
| Short-term assets per $1 of bills due | 2.05× | Best in this row: 2.28× |
| Dividend yield | Best in this row: 0.58% | 0.44% |
| Share of profit paid as dividends | Best in this row: 20% | 29% |
| Our readPro | ||
| Our call | Buy more | Keep |
| Why | Agilent's sales grew 8.6% over the past year, and it trades at 28 times its past year's earnings, close to its usual level. | Analysts expect Bio-Techne's profit to grow 15% next year, but its sales grew only 0.9% over the past year. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | Best in this row: 70 | 41 |
| Our value score | Best in this row: 68 | 11 |
| Our growth score | Best in this row: 65 | 35 |
| Our quality score | Best in this row: 84 | 68 |
| Our price trend score | Best in this row: 69 | 49 |
| Earnings and analysts | ||
| Next earnings | Nov 23AMCin 11 days | Nov 11in undefined days |
| Analyst consensus | Buy | Hold |
| To average analyst target | Best in this row: +3.8% | +0.3% |
| Average analyst target | $183.60 | $73.00 |
| Analysts rating it a buy | Best in this row: 68% | 0% |
| Buy ratings added, 3 months | −2 | −2 |
| Analysts covering | 15 | 3 |
A: our only Buy more, with faster sales growth
Our pick of these: Agilent Technologies
Sales growth +8.6% vs +0.9%
A +8.6%, TECH +0.9%.Forward P/E per point of sales growth 3.09 vs no growth
A 3.09, TECH no growth.+3.8% to the average analyst target, vs +0.3%
A +3.8%, TECH +0.3%.Where it loses: TECH has a better past year, +23.7% vs +19.3%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.